In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...
The companies plan to test the treatment's efficacy in preclinical models of squamous cell lung carcinoma early next year.
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
Morning Overview on MSN
Crispr reveals a new way to defeat resistant lung cancer
Drug resistance has long turned some of the most advanced lung cancer therapies into temporary victories, with tumors ...
The nuclear factor E2-related factor 2 (Nrf2) is a master transcriptional activator of genes encoding numerous cytoprotective enzymes that are induced in response to environmental and endogenously ...
The screening of breast cancer awareness and health behaviors of women age 40 to 69 in Mus, the least developed city in Turkey: A population based, cross-sectional study. This is an ASCO Meeting ...
Caloric restriction (CR) is the most potent intervention known to both protect against carcinogenesis and extend lifespan in laboratory animals. A variety of anticarcinogens and CR mimetics induce and ...
Research published today in the Journal of Hepatology suggests that the protein responsible for antioxidant defenses in humans may adversely affect the liver. The research was led by postdoctoral ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback